TIDMAGY
RNS Number : 0997U
Allergy Therapeutics PLC
31 March 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Vesting of Awards under Long Term Incentive Plan,
Increase to Block Listing
and
Total Voting Rights
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, announces
that :
Vesting of Award
Performance conditions attaching to provisional awards
("Awards") made pursuant to the Company's Long Term Incentive Plan
("LTIP") for the three years ended 15 March 2021, details of which
were announced on 16 March 2018, have been met in part.
Consequently, on 30 March 2021, Allergy Therapeutics granted
certain of its director's options ("Options") over the Company's
Ordinary Shares in replacement for the Awards made under the LTIP
as follows:
Director Percentage Total number Exercise Price
of Award Vested of Ordinary Shares
over which Options
granted
M anuel L lobet 50% 450,000 0.1 pence
----------------- ------------------- --------------
Nicolas Wykeman 50% 225,000 0.1 pence
----------------- ------------------- --------------
In accordance with the rules of the LTIP, 50% of these Options
are exercisable immediately and the remaining 50% are subject to a
holding period of three years. The exercise period is ten years
from date of grant.
Following the above share transactions, the Executive Directors
hold the following:
Director Unvested LTIP Options Interest in Ordinary
Awards Shares
Manuel Llobet 2,700,000 872,500 3,325,000
-------------- -------- ---------------------
Nicolas Wykeman 1,350,000 436,250 300,000
-------------- -------- ---------------------
Increase to Block Listing
Allergy Therapeutics announces that application has been made
for admission to trading on AIM in respect of an additional block
listing of 7,000,000 Ordinary Shares to become effective on 7 April
2021.
The Ordinary Shares may be issued pursuant to the exercise of
share options under the Company's LTIP and will, upon issue, rank
pari passu in all respects with the Company's existing Ordinary
Shares. Following this increase, the total Block Listing will
consist of 10,177,235 Ordinary Shares.
Total Voting Rights
Allergy Therapeutics also announces that pursuant to its block
admission facility, details of which were announced on 20 November
2017, it has recently issued 148,369 Ordinary Shares in
satisfaction of the exercise of share options. The new Ordinary
Shares rank pari passu with the Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, as at 30
March 2021, the Company has 640,940,533 Ordinary Shares in issue.
There are no shares held in treasury. The total number of voting
rights in the Company is therefore 640,940,533.
The above figure of 640,940,533 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Manuel Llobet
--------------------- -------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Manuel Llobet - Chief Executive Office and PDMR
--------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--------------------- -------------------------------------------------
b) LEI LEIR97215202003301009534776
--------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description Conditional award of shares and grant of share
of the financial options under the Company's Long Term Incentive
instrument, Plan
type of instrument
--------------------- -------------------------------------------------
b) Identification GB00B02LCQ05
code
--------------------- -------------------------------------------------
c) Nature of the Grant of conditional Awards
transaction
--------------------- -------------------------------------------------
d) Price(s) and Awards Price(s) Volume(s)
volume(s) Options 0.1 pence 450,000
--------------------- -------------------------------------------------
e) Aggregated
information n/a
--------------------- -------------------------------------------------
f) Date of the 30 March 2021
transaction
--------------------- -------------------------------------------------
g) Place of the Outside a trading venue
transaction
--------------------- -------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nicolas Wykeman
--------------------- -------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Nicolas Wykeman - Chief Financial Officer and
PDMR
--------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--------------------- -------------------------------------------------
b) LEI LEIR97215202003301009534776
--------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description Conditional award of shares and grant of share
of the financial options under the Company's Long Term Incentive
instrument, Plan
type of instrument
--------------------- -------------------------------------------------
b) Identification GB00B02LCQ05
code
--------------------- -------------------------------------------------
c) Nature of the Grant of conditional awards
transaction
--------------------- -------------------------------------------------
d) Price(s) and Awards Price(s) Volume(s)
volume(s) Options 0.1 pence 225,000
--------------------- -------------------------------------------------
e) Aggregated
information n/a
--------------------- -------------------------------------------------
f) Date of the 30 March 2021
transaction
--------------------- -------------------------------------------------
g) Place of the Outside a trading venue
transaction
--------------------- -------------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.600 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAXDFDAXFEEA
(END) Dow Jones Newswires
March 31, 2021 03:29 ET (07:29 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
